左卡尼汀辅助持续低效缓慢血液透析治疗终末期糖尿病肾病的疗效 及对患者生存质量和氧化应激指标的影响. (Chinese)

Objective: To evaluate the efficacy of levocarnitine assisted sustained low-effciency dialysis (SLED) in the treatment of end-stage DN and its impact on patients’ quality of life and oxidative stress indicators. Methods: Sixty end-stage DN patients admitted to our hospital from March 2020 to February 2023 were randomly divided into a matched group and an observation group, with 30patients in each group. Both groups were treated with SLED, while the observation group was treated with levocarnitine for 3 months.Evaluate and compare the clinical efficacy, quality of life and oxidative stress indicators between the two groups. Results: The total effective rate of the observation group was higher than that of the matched group (P＜0.05), while the total incidence of adverse reactions was lower than that of the matched group (P＜0.05). After treatment, the serum Na + and Alb levels in the observation group were higher than those in the matched group, while the K + , SCr, BUN and β2-MG levels were significantly lower than those in the matched group (P＜0.05). Compared to before treatment, MDA and AOPPs were significantly reduced, while SOD and GSP-Px were significantly increased in both groups after treatment (P＜0.05), while the decrease/increase amplitude in the observation group was greater than that in the matched group (P＜0.05). There was no difference in the SF-36 scale scores between the two groups before treatment (P＞0.05), but after treatment, the SF-36 scale scores in the observation group were higher than those in the matched group (P＜0.05). Conclusion: The efficacy of levocarnitine assisted SLED in the treatment of end-stage DN is clear, which can effectively inhibit the body’s oxidative stress response, reduce adverse reactions, and improve the quality of life of patients. [ABSTRACT FROM AUTHOR]

评价左卡尼汀辅助持续低效缓慢血液透析（SLED）治疗终末期糖尿病肾病（DN）的疗效及对患者生存质量和氧化应激 指标的影响。方法：选入我院 2020 年 3 月 ~2023 年 2 月收治的终末期 DN 患者 60 例，随机分为对照组和观察组，各 30例。两组 均予以 SLED 治疗，观察组加用左卡尼汀，疗程 3 个月。评价两组的临床疗效、生存质量、氧化应激指标等，并进行统计比较。结 果：观察组治疗总有效率较对照组高（P＜0.05），而不良反应总发生率较对照组低（P＜0.05）；观察组治疗后血清 Na+、Alb显著高 于对照组，K + 、SCr、BUN、茁2-MG 水平明显低于对照组（P＜0.05）；相较于治疗前，两组治疗后 MDA、AOPPs明显降低，SOD、 GSP-Px 显著升高（P＜0.05），而观察组降低 / 升高幅度明显大于对照组（P＜0.05）；两组治疗前 SF-36 量表评分无差异（P＞0.05）， 治疗后，观察组 SF-36 量表各项评分均显著高于对照组（P＜0.05）。结论：左卡尼汀辅助 SLED治疗终末期 DN的疗效明确，可有 效抑制机体的氧化应激反应，减少不良反应，提高患者的生存质量。 [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)